Skip to main navigation
  • Our Product
  • Investors

    Investor Relations

    • Investor Relations
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources
Fennec Pharmaceuticals
  • Our Product
  • Investors
    • Investor Relations
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources

    Investor Relations

    • Investor Relations
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources

You are here: Home / Investors

    Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

    • Read more about Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

    Fennec Pharmaceuticals Announces Management Change

    • Read more about Fennec Pharmaceuticals Announces Management Change

    Fennec Announces Results of Annual Meeting

    • Read more about Fennec Announces Results of Annual Meeting

    Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

    • Read more about Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

    Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

    • Read more about Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

    Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

    • Read more about Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

    Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

    • Read more about Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

    Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

    • Read more about Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

    Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

    • Read more about Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

    FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

    • Read more about FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

    Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page 1
    • Current page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page Next ›
    • Last page Last »
    Subscribe to

    Investor Tools

    • Print Page
    • Email Alerts
    • Contact IR
    • RSS Feeds

    Investor Relations

    • Investor Relations
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources
    Copyright © 2025 Fennec Pharmaceuticals
    Scroll to top